Tate Shinichi, Nishikimi Kyoko, Matsuoka Ayumu, Otsuka Satoyo, Shiko Yuki, Ozawa Yoshihito, Kawasaki Yohei, Shozu Makio
Department of Gynecology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan.
Biostatistics Section, Clinical Research Center, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan.
Cancers (Basel). 2021 Jun 25;13(13):3177. doi: 10.3390/cancers13133177.
(1) Background: We investigated survival outcomes following first-line chemotherapy before and after approval of bevacizumab (Bev) for ovarian cancer in Japan to evaluate the efficacy of Bev for advanced clear cell carcinoma (CCC). (2) Methods: We investigated 28 consecutive patients diagnosed with CCC (stages III/IV) at our hospital between 2008 and 2018. Bev was administered for treatment of advanced CCC after approval in Japan in November 2013. Progression-free survival (PFS) was compared between 10 patients treated before Bev approval (2008-2013, Bev- group) and 18 patients treated after Bev approval (2014-2018, Bev+ group) for first-line chemotherapy. (3) Results: No intergroup difference was observed in patient characteristics. The rate of completeness of resection was higher in the Bev - group (9/10, 90%) than in the Bev+ group (15/18, 83%) ( = 0.044). Eleven (61%) patients in the Bev + group received ≥ 21 cycles of Bev. The median PFS increased from 12.0 months before Bev approval to 29.8 months after Bev approval (Wilcoxon test, = 0.026). Multivariate analysis showed that performance status ( = 0.049), Bev administration ( = 0.023) and completeness of resection ( = 0.023) were independent prognostic factors for PFS. (4) Conclusions: Bev incorporated into first-line chemotherapy might improve PFS in patients with advanced CCC. We hope that our findings will be confirmed in adequate clinical trials.
(1) 背景：我们调查了在日本贝伐单抗（Bev）获批用于卵巢癌前后一线化疗后的生存结局，以评估Bev对晚期透明细胞癌（CCC）的疗效。(2) 方法：我们调查了2008年至2018年间在我院连续诊断为CCC（III/IV期）的28例患者。Bev于2013年11月在日本获批后用于治疗晚期CCC。比较了10例在Bev获批前接受治疗的患者（2008 - 2013年，Bev-组）和18例在Bev获批后接受治疗的患者（2014 - 2018年，Bev+组）一线化疗的无进展生存期（PFS）。(3) 结果：两组患者特征无组间差异。Bev -组的切除完整性率（9/10，90%）高于Bev+组（15/18，83%）（P = 0.044）。Bev+组中有11例（61%）患者接受了≥21个周期的Bev治疗。Bev获批前的中位PFS为12.0个月，获批后的中位PFS增加至29.8个月（Wilcoxon检验，P = 0.026）。多因素分析显示，体能状态（P = 0.049）、Bev给药（P = 0.023）和切除完整性（P = 0.023）是PFS的独立预后因素。(4) 结论：将Bev纳入一线化疗可能改善晚期CCC患者的PFS。我们希望我们的研究结果能在充分的临床试验中得到证实。
Zotero 插件